• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
MIRM

MIRM

Mirum Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD91.83

-0.34 (-0.36%)

Rating:D+

Company Profile

CEO

Christopher Peetz

IPO Date

2019-07-18

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$92.00

Prev. Close

$92.17

Day Low

$90.59

Day High

$92.67

52W Low

$43.50

52W High

$114.99

Market Cap

$4.61B

Volume

0.61M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

31.4%

Avg Negative

2.1%

Avg Neutral

66.2%

News Feed

Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea

Business Wire·7/26/2021·↑ positive

Mirum Pharmaceuticals to Present at Piper Sandler's Virtual EASL Takeaway Day

Business Wire·6/24/2021·↑ positive

Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting

Business Wire·6/3/2021·↑ positive

Mirum Pharmaceuticals' (MIRM) CEO Chris Peetz on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research·3/9/2021·↑ positive

Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign

Business Wire·1/24/2021·↑ positive

Mirum Pharmaceuticals (MIRM) in Focus: Stock Moves 5.9% Higher

Zacks Investment Research·12/22/2020·↑ positive

Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Business Wire·12/14/2020·↑ positive

Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Business Wire·12/14/2020·↑ positive